Ascendis gets USD 150m in cash from selling synthetic royalty

Starting January 2025, Royalty Pharma will receive a share of the revenue from the sale of weekly growth hormone Skytrofa in the US.

by MIKKEL AABENHUS HEMMINGSEN

Biotech company Ascendis and Royalty Pharma have entered into an agreement that secures the former an upfront payment of USD 150m.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.

Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

For subscribers

Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers

Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Foto: Pr

Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

For subscribers

Pharma & biotech

Pharmaceutical industry to grow 4% annually towards 2030

For subscribers

Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers

Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom
The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.
For subscribers
FDA approves Novo Nordisk drug to treat rare condition
The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.
For subscribers
Fujifilm expands management with former Leo executive
The contract manufacturer has hired a chief people officer with immediate effect.
For subscribers
Low share price may knock Galecto off the stock exchange
Nasdaq has requested that the biotech company raise its share price to above USD 1.
For subscribers
Snack maker keeps an eye on Novo Nordisk's obesity drug
”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.
Olympus appoints new chief medical officer
The new medical director is brought in from Medtronic.
For subscribers

Ascendis CFO sells shares worth DKK millions

The deal happens just over a week after Ascendis began the rollout of its weekly growth hormone, Skytrofa, in Europe.

For subscribers

Hearing health

Departing CEO on leaving GN: My own decision

There have been talks between Gitte Aabo, CEO of GN, and the board of directors of the audio group for a long time about a possible stop, according to the former.

For subscribers

Pharma & biotech

Ascendis to launch weekly growth hormone i first European country this september

The launch comes more than a year and a half after approval.

For subscribers

Scott Thomas Smith, CFO of Ascendis Pharma. | Foto: Ascendis Pharma / Pr

Pharma & biotech

Sale of royalties marks new approach to funding for Ascendis

Ascendis has historically raised capital through share issues, but that way of business is coming to an end.

For subscribers

Pharma & biotech

Genmab and Abbvie receives EU clearance to market cancer drug

The drug has previously received a positive recommendation from European Medicines Agency, while it was launched in the US by the end of the second quarter.

For subscribers